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Purpose: To systematically review studies that examined the influence of the CYP1A2 23 
−163C>A polymorphism on the ergogenic effects of caffeine and to discuss some of the 24 
reasons for the discrepancies in findings between the studies.  25 
Methods: This review was performed in accordance with the PRISMA guidelines. The search 26 
for studies was performed through nine databases.  27 
Results: Seventeen studies were included in the review. Based on the included studies, it 28 
seems that individuals with the AA or AC/CC genotype may experience an increase in 29 
performance following caffeine ingestion. Significant differences between genotypes were 30 
found in four studies, and all four reported a more favorable response in the AA vs. AC/CC 31 
genotype. These results suggest that if there is an actual genotype-related effect of acute 32 
caffeine supplementation, it might be in that direction. In the studies that reported such data 33 
for aerobic endurance, the findings are specific to male participants performing cycling time 34 
trials (distances of ≥10 km) and ingesting caffeine 60 minutes before exercise. For high-35 
intensity exercise, two studies reported that genotype variations determined the response to 36 
caffeine ingestion, even though the differences were either small (~1 additional repetition in 37 
high-load resistance exercise set performed to muscular failure) or inconsistent (i.e., observed 38 
only in one out of eight performance tests).  39 
Conclusions: CYP1A2 genotype variations may modulate caffeine's ergogenic effects, but the 40 
differences between genotypes were small, inconsistent, or limited to specific exercise 41 
scenarios. Future studies with larger sample sizes are needed to fully elucidate this research 42 
area.  43 




Caffeine is one of the most consumed psychoactive drugs in the world [1]. Besides the 46 
general population, caffeine is also widely used by athletes because of its ergogenic effects on 47 
exercise performance [2]. Based on the available evidence, caffeine ingestion may be 48 
ergogenic for different components of exercise performance, such as aerobic and muscular 49 
endurance, muscle strength, power, and speed [3]. Such effects are well-established and well-50 
replicated in the scientific literature [3]. However, the response to caffeine ingestion does not 51 
seem to be uniform across individuals, with some experiencing increases in performance 52 
following acute caffeine ingestion, while others show no performance-related changes or even 53 
decrease following caffeine consumption [4].  54 
 55 
The gene CYP1A2 encodes cytochrome P450 1A2, an enzyme responsible for ~95% of 56 
caffeine metabolism [5]. An A to C substitution at position 163 (−163C>A; rs762551) in the 57 
CYP1A2 gene impacts the speed of caffeine metabolism [6]. Individuals who possess the AA 58 
genotype are considered “fast metabolizers” of caffeine, given that this genotype codes for the 59 
highly inducible form of the CYP1A2 enzyme [5-8]. Individuals with AC or CC genotype 60 
(i.e., C allele carriers) tend to have slower caffeine metabolism and are considered as “slow 61 
metabolizers” of caffeine [5-8].  62 
 63 
Several studies explored the effects of caffeine supplementation on exercise performance 64 
while considering CYP1A2 −163C>A polymorphism [9-13]. The results of these studies, 65 
however, are equivocal. Some studies found genotype differences in caffeine’s ergogenic 66 
effects, as individuals possessing the AA genotype experienced improvements in performance 67 
following caffeine ingestion, while those with the AC or CC genotype were not positively 68 
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impacted by caffeine ingestion [12]. In contrast to these findings, others have suggested that 69 
individuals with the AC genotype experience greater improvements in performance following 70 
caffeine ingestion than those who possess the AA genotype [13]. Finally, some studies did not 71 
show significant differences in responses to caffeine supplementation between genotypes [9-72 
11].  73 
 74 
Given the equivocal evidence presented in the literature, we aimed to: (a) systematically 75 
review the available studies that have examined the influence of the CYP1A2 −163C>A 76 
polymorphism on the ergogenic effects of caffeine; and, (b) discuss some of the reasons for 77 
the discrepancies between the studies. A systematic review of the evidence might be of high 78 
practical importance as it may help to identify why some individuals have minimal ergogenic 79 
or even ergolytic effects after acute caffeine intake. The presented findings might also be of 80 
relevance if we consider that the number of companies that offer direct-to-consumer genetic 81 
testing aimed to detect individual responses to caffeine and the subsequent popularity of such 82 
testing has experienced a substantial increase in recent years [14].  83 
 84 
Methods 85 
Search strategy 86 
This review was performed while following the Preferred Reporting Items for Systematic 87 
Reviews and Meta-Analyses (PRISMA) guidelines [15]. The protocol was not registered. For 88 
the purpose of this review, we performed a comprehensive search of the following databases: 89 
CINAHL, ERIC, Open Dissertations, Networked Digital Library of Theses and Dissertations, 90 
Open Access Theses and Dissertations, PubMed/MEDLINE, Scopus, SPORTDiscus, and 91 
Web of Science. In all of these databases, we used the following syntax: (CYP1A2 OR 92 
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genotype OR genetics OR polymorphism) AND (caffeine) AND (exercise OR training OR 93 
ergogenic OR performance). Secondary searches were performed by examining the reference 94 
lists of all included studies and by performing forward citation tracking through Google 95 
Scholar and Scopus. The search for studies concluded on August 28th, 2020 and was 96 
performed independently by two authors (JG and CP) of the review to minimize bias in study 97 
selection.  98 
 99 
Inclusion criteria and data extraction  100 
We included studies that satisfied the following criteria: (a) written in English as a peer-101 
reviewed paper, a thesis, or a dissertation; (b) explored the influence of any of the CYP1A2 102 
−163C>A genotypes on the ergogenic responses to acute caffeine ingestion; (c) included 103 
humans as study participants. We extracted the following data from the included studies: (a) 104 
author(s) and publication status (i.e., published or unpublished); (b) sample size, CYP1A2 105 
genotype distribution, and participants’ characteristics (sex, age, body mass, habitual caffeine 106 
intake, and training status); (c) caffeine supplementation protocol and exercise task(s); and (d) 107 
main study findings (i.e., caffeine main effects and caffeine × genotype interaction, where 108 
applicable).  109 
 110 
Calculation of effect sizes 111 
Where available, Cohen’s d effect sizes were calculated as the caffeine-placebo mean change 112 
divided by the pooled SD, separately for each genotype. Effect sizes were interpreted as: 113 




Methodological quality 116 
The 11-point PEDro scale was used to assess the methodological quality of the included 117 
studies [16]. In line with the recommendations, item 1 on the PEDro scale was not included in 118 
the total score as it concerns external validity. Besides external validity, items on the checklist 119 
refer to randomization, concealed allocation, blinding, attrition, and data reporting. Each item 120 
is scored with a 1 (criterion satisfied) or with a 0 (criterion not satisfied or unclear). The 121 
maximal score on the PEDro checklist was 10. We classified studies as “excellent” quality (9–122 
10 points), “good” quality (6–8 points), “fair” quality (4–5 points), or “poor” methodological 123 
quality (≤3 points) [17]. Two authors (JG and PM) independently performed the 124 
methodological quality assessment; any observed differences in the initial scoring were 125 
resolved via discussion. 126 
 127 
Results 128 
Study selection 129 
In the primary search, there was a total of 1621 potentially relevant references. Of the 1621 130 
screened references, 1593 were excluded based on title or abstract; 28 full-text papers were 131 
read, and 14 studies were included in the review. Secondary searches resulted in another 1684 132 
search results, and with the inclusion of three additional studies (Figure 1). Therefore, the 133 
final number of included studies was 17 [9-13, 18-29]. Fourteen studies were published in 134 
peer-reviewed journals; two were theses [20, 25], and one was a dissertation [21]. 135 
 136 
Aerobic endurance 137 
8 
 
Eleven studies explored the influence of CYP1A2 −163C>A polymorphism on the responses 138 
to caffeine ingestion during aerobic exercise (Table 2). Of these studies, eight combined the 139 
AC and CC genotype in one group and compared it to the AA genotype groups; two studies 140 
compared the effects across all three genotypes (Table 1). Additionally, in one study, only a 141 
main effect of caffeine was explored in a sample consisting exclusively of 14 participants 142 
with the AC genotype [25]. Sample sizes in individual studies ranged from 11 to 101 143 
participants (pooled number of participants: 396). All studies included either a mixed-sex 144 
sample or included only men. A significant main effect of caffeine was observed in all 145 
studies, except in the study by Algrain et al. [9], where there were no significant differences 146 
between caffeine and placebo. A significant caffeine × genotype interaction was found in two 147 
studies [12, 26]. In one, a greater ergogenic effect was found in the AA genotype as compared 148 
to AC/CC genotype [26]. In another, an ergogenic effect was found in the AA genotype with 149 
both used caffeine doses (2 and 4 mg/kg); no increases in performance in the AC genotype 150 
occurred with any of the used caffeine doses, and decreases in performance in the CC 151 
genotype with the consumption of 4 mg/kg of caffeine, but not 2 mg/kg of caffeine [12]. 152 
Across the individual studies, effect sizes of caffeine on performance for the AA genotype 153 
ranged from 0.16 to 0.67 (Table 2). For the AC/CC genotype, effect sizes ranged from 0.07 to 154 
0.36. In the two studies that presented data for the CC genotype, the effect size amounted to –155 
1.35 (favoring of placebo) in one study [12], and 0.12 (favoring of caffeine) in another [29].  156 
 157 
High-intensity exercise 158 
Eight studies explored the influence of CYP1A2 −163C>A polymorphism on the responses to 159 
caffeine ingestion during high-intensity exercise (Table 2). The performance tests in these 160 
studies included muscle endurance tasks in resistance exercise, isometric handgrip strength 161 
tests, jumping (countermovement jump, spike jump, and squat jump), sprinting (Wingate test, 162 
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sprint velocity test), agility tests, and sport-specific (tennis and handball) skill tests. Of these 163 
studies, six conducted a comparison of effects between the AA and AC/CC genotype, one 164 
compared the effects across all three genotypes, and in one study [25], only a main effect of 165 
caffeine was explored in a sample of participants with the AC genotype (Table 1). Across the 166 
studies, sample sizes ranged from 14 to 100 participants (pooled number of participants: 253). 167 
Four studies included a mixed-sex sample, and four included only men (Table 1). Significant 168 
main effects of caffeine were observed in all studies, but not necessarily across all exercise 169 
tasks, as some studies [22, 28, 29] did not find significant differences between caffeine and 170 
placebo for agility tests, isometric handgrip strength, or ball velocity throw tests. A significant 171 
caffeine × genotype interaction was found in two studies [23, 28]. In one study, resistance 172 
exercise performance was enhanced following caffeine ingestion in the AA genotype, while 173 
no ergogenic effects were observed in the AC/CC genotype [23]. In another study, a 174 
significant caffeine × genotype interaction was found in one out of eight performance tests 175 
(ball throw from 7-m), with ergogenic effects observed for the AA, but not AC/CC genotype 176 
[28]. Effect sizes of caffeine on performance for the AA genotype ranged from 0.0 to 1.87 177 
(Table 2). For the AC/CC genotype, effect sizes ranged from –0.23 to 1.27. In the only study 178 
that presented data separately for the CC genotype, the effect sizes ranged from –0.37 to 0.36. 179 
            180 
Methodological quality 181 
The average score on the PEDro checklist was 8.6 points (range: 7 to 9 points). Thirteen 182 
studies were classified as “excellent” methodological quality, and four as “good” 183 
methodological quality. Individual scores are presented in Table 3.   184 
 185 
Discussion  186 
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Based on the results presented in the current literature, it generally seems that individuals with 187 
the CYP1A2 AA or AC/CC genotype may experience an increase in performance following 188 
caffeine ingestion. Four included studies found significant differences between AA and AC or 189 
CC genotype, and in all of these studies, the effects of caffeine favored the AA genotype. 190 
These results suggest that if there is a true genotype effect in the population, it might be in 191 
that direction. Still, several important factors that might be responsible for the discrepancies in 192 
findings and the practical relevance of the results need to be considered when interpreting 193 
these findings. 194 
 195 
Aerobic endurance  196 
Of the studies that examined the effects of caffeine on measures of aerobic endurance, only 197 
two reported significant caffeine × genotype interaction, whereby individuals with the AA 198 
genotype experienced greater improvements in exercise performance than the participants 199 
with the AC/CC genotype [12, 26]. These studies used either 10-km or 40-km cycling time 200 
trials. Some studies that reported no significant caffeine × genotype interaction used shorter 201 
duration time trials (e.g., 3-km in two studies; [11, 13]). In the study by Pataky et al. [13], the 202 
increases in performance even favored the AC genotype, even though the difference was not 203 
statistically significant (p = 0.12). Therefore, significant between-genotype differences in 204 
response to caffeine supplementation may be only present in longer duration aerobic events. 205 
This hypothesis seems plausible, given that the effects of caffeine may increase with the 206 
increase in the duration of the aerobic task [30]. However, one study explored the effects of 207 
caffeine using Olympic-distance triathlons as the exercise task and did not find caffeine × 208 
genotype interaction (even though a main effect of caffeine was observed), suggesting that the 209 




In the two studies that reported significant differences between the genotypes, the samples 212 
consisted exclusively of men [12, 26]. All studies that included a mixed-sex sample did not 213 
report significant differences in response to caffeine ingestion between genotypes (Table 2). 214 
As men and women seem to experience a similar response to caffeine ingestion during 215 
aerobic exercise, it does not seem that the inclusion of a mixed-sex sample should be 216 
considered as a limitation of these studies [31, 32]. Albeit speculative, it is conceivable that 217 
genotype differences impact the individual variation in response to caffeine ingestion in men, 218 
but not in women. In support of this hypothesis, there is evidence that CYP1A2 activity is 219 
lower in women than men, which might explain these inconsistent findings [33]. Instead of 220 
excluding females, future research should consider including both males and females and plot 221 
the data separately to see if there indeed is a difference between sexes.  222 
 223 
One potentially confounding issue is that studies generally did not report if the participants 224 
were current smokers. This might be important given that smoking may affect CYP1A2 225 
activity. A recent meta-analysis reported that only smokers demonstrated differences in 226 
CYP1A2 activity between the AA vs. CC and AC vs. CC genotype [34]. In a subgroup of 227 
studies that included non-smokers, no differences were found in CYP1A2 activity between 228 
genotypes. In non-smokers, only in heavy coffee consumers (more than 3 cups per day), the 229 
AA genotype had higher CYP1A2 activity than in C allele carriers [35]. In the two studies 230 
that specifically noted that the participants were non-smokers, the authors did not find 231 
significant caffeine × genotype interaction [9, 20]. Future studies on the topic should specify 232 
the information on the smoking status of the participants to allow for a more informed 233 
comparison of results between the studies. Other factors, such as vegetable intake [36], phase 234 
of the menstrual cycle [37], and oral contraceptive use [38], may also affect caffeine 235 
metabolism, and they should be considered in future studies. While potentially relevant, some 236 
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of these factors may not impact caffeine’s ergogenic effects, as recent studies observed 237 
similar improvements in exercise performance following caffeine ingestion in the early 238 
follicular, pre-ovulatory, and mid-luteal phases of the menstrual cycle [39, 40]. 239 
 240 
Future research is needed to explore the influence of caffeine ingestion timing, as some have 241 
hypothesized that different effects may be observed when using longer waiting times from 242 
caffeine ingestion to the start of the exercise session [41]. Specifically, given that C allele 243 
carriers are considered slow caffeine metabolizers, they might need to ingest caffeine 90 or 244 
120 minutes before exercise to experience ergogenic effects [41]. There might be some 245 
credence to this hypothesis if we consider the finding by McGrath [20]. In this study, the main 246 
performance task consisted of a 30-minute cycling time trial performed 175 minutes 247 
following caffeine ingestion. The participants ingested caffeine 60-minutes before performing 248 
115-minutes of steady-state cycling. Only after steady-state cycling, the participants 249 
performed the main performance trial. A main effect of caffeine was observed, but no caffeine 250 
× genotype interaction, suggesting that similar responses to caffeine supplementation between 251 
genotypes occurred, possibly because of the timing of caffeine supplementation. A limitation 252 
of the study is that the participants first performed steady-state cycling. This aspect of the 253 
study design is important to mention given that exercise may impact CYP1A2 activity [42]. 254 
Furthermore, the study by McGrath [20] had a small sample of 11 participants, and this 255 
limitation should be considered when interpreting these findings.  256 
  257 
Overall, there is some evidence that CYP1A2 −163C>A polymorphism may impact the 258 
ergogenic effects of caffeine on aerobic endurance. While individuals that possess the AC/CC 259 
genotype still may experience improvements in performance, there is some evidence 260 
indicating that AA homozygotes obtain a higher ergogenic effect from acute caffeine intake 261 
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than C allele carriers. However, to date, such findings are observed only in: (a) male 262 
participants; (b) cycling time trials that included a ≥10 km distance; and (c) protocols that 263 
included caffeine ingestion 60 minutes before exercise. 264 
 265 
High-intensity exercise  266 
Of the eight studies that used high-intensity exercise tasks, two reported a significant caffeine 267 
× genotype interaction [23, 28]. In one study [28] conducted among 31 professional handball 268 
players, significant genotype differences were observed in ball throw velocity from 7-m. This 269 
study found improvements in individuals with the AA genotype following caffeine ingestion, 270 
whereas participants with the AC/CC genotype did not benefit from caffeine ingestion on this 271 
specific test. However, these results were inconclusive given that no significant genotype 272 
differences were observed for other similar outcomes, such as ball throw velocity from 9-m, 273 
and ball throw velocity from 7 and 9-m with a goalkeeper. In another study, individuals who 274 
possessed the AA genotype experienced improvements in resistance exercise performance 275 
following the ingestion of 6 mg/kg of caffeine [23]. Exercise performance did not improve 276 
following caffeine ingestion in those with the AC/CC genotype. It should be noted, however, 277 
that the difference in exercise performance was small. Specifically, following caffeine 278 
ingestion, the AA genotype group completed an average of one repetition more (range: 0.3 to 279 
1.1 repetitions) in a set with 85% of one-repetition maximum (1RM) performed to momentary 280 
muscular failure. In the AC/CC group, the number of performed repetitions was the same 281 
following placebo and caffeine ingestion. A subsequent study performed by Grgic et al. [18] 282 
did not find a caffeine × genotype interaction using the same exercise task as Rahimi [23], 283 




Besides assessing the number of repetitions, Grgic et al. [18] also assessed the velocity and 286 
power output of each repetition. For the analysis, these authors also matched the number of 287 
performed repetitions between caffeine and placebo conditions and observed that caffeine 288 
ingestion substantially affected the “quality” of performed repetitions in both genotypes. In 289 
the Rahimi [23] study, the only assessed outcome was the quantity of performed repetitions, 290 
but not its overall quality. From a practical perspective, the quality of repetitions may be of 291 
greater relevance. As shown by studies that used velocity-based training, training at a lower 292 
velocity loss often produces similar or superior training adaptations as training at a higher 293 
velocity loss, despite the higher number of repetitions performed when training at a higher 294 
velocity loss [43, 44]. Future studies should assess both the quantity and quality of performed 295 
repetition to reconcile these equivocal findings.  296 
 297 
Besides resistance exercise, studies also utilized other high-intensity tasks, such as jumping 298 
and Wingate test performance [18, 22, 24]. None of these studies found a significant caffeine 299 
× genotype interaction in the analyzed outcomes, even though most reported a significant 300 
main effect of caffeine. In line with these observations, the study by Southward [25]—that 301 
included only 14 participants with the AC genotype—also reported improvements in 302 
resistance exercise and jumping performance following caffeine ingestion. The effect size in 303 
this study was similar to the effects of caffeine previously reported among samples with the 304 
AA genotype and among those that were not genotype-specific [18, 22, 45, 46]. 305 
 306 
A limitation of the majority of studies conducted on the topic is pooling the AC and CC 307 
genotype into a single group, which is relevant as the response may not be uniform across 308 
these two genotypes [12]. Out of the studies that utilized high-intensity exercise tasks, only 309 
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one large sample size (n = 100) study examined the effects across all three genotypes [29]. 310 
This study did not find significant genotype differences, even though caffeine ingestion 311 
enhanced muscular endurance (but not isometric strength, agility, and jump height). Still, this 312 
study is also unique by the inclusion of adolescents as study participants, given that all other 313 
studies included young adults. Overall, based on the current body of evidence, CYP1A2 314 
genotype variations might impact the ergogenic effect of caffeine supplementation on high-315 
intensity exercise performance. However, the differences between genotypes were either 316 
small or inconsistent, highlighting the need for future research.  317 
 318 
Methodological considerations  319 
Some of the discrepancies in findings between studies might also be related to the source and 320 
dose of caffeine. Guest et al. [12] demonstrated ergolytic effects of caffeine in the CC 321 
genotype with the consumption of 4 mg/kg of caffeine, but not 2 mg/kg of caffeine. Two 322 
additional studies [23, 26] that observed genotype differences also used a higher dose of 323 
caffeine (i.e., 6 mg/kg). These results suggest that the dose might influence CYP1A2 genotype 324 
responses to acute caffeine ingestion. Still, it should be noted that other studies [13, 29] also 325 
used higher doses of caffeine and did not find genotype differences, suggesting that dose 326 
alone is not likely the sole explanation for the differences in findings.  327 
 328 
There is growing evidence that consuming alternate sources of caffeine such as chewing gums 329 
and caffeine gels may enhance exercise performance [47]. One included study [9] used 330 
chewing gums and did not observe general ergogenic effects of caffeine. The lack of an 331 
ergogenic might be because an absolute dose of 255 mg was used, which might have created 332 
differences in responses due to variation in body mass among participants. In contrast, 333 
caffeine’s ergogenic effect is most commonly observed when providing relative doses ranging 334 
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from 3 to 6 mg/kg [48]. To avoid confounding factors such as the absence of an ergogenic 335 
effect (due to administration of absolute caffeine doses), future studies that aim to explore the 336 
influence of genotype on the response to caffeine ingestion should strive to employ optimal 337 
protocols of caffeine supplementation that include providing dose relative to body mass. 338 
 339 
Factors such as participants’ training status and their habitual caffeine intake should also be 340 
considered when interpreting the evidence [49-51]. In all four studies [12, 23, 26, 28] that 341 
reported significant between-genotype differences, the participants were either athletes or 342 
resistance-trained individuals. This might suggest that caffeine’s effects, according to the 343 
CYP1A2 genotype, might be related to training status. However, other studies [18, 29] also 344 
included trained individuals but did not observe genotype differences, highlighting the 345 
equivocal nature of the evidence. Future studies on the topic may consider including trained 346 
and untrained individuals to establish a relationship between caffeine’s ergogenic effects, 347 
training status, and CYP1A2 genotype. Most studies included participants that were “low” 348 
habitual caffeine intake users (Table 2). Therefore, from this standpoint, the included studies 349 
were reasonably uniform. Still, some studies [26, 27] included “low”, “moderate”, and “high” 350 
habitual users as study participants, which might be a limitation as there is evidence indicating 351 
that habitual caffeine intake may influence the ergogenic effects of acute caffeine ingestion 352 
[50, 51]. Therefore, when conducting studies on this topic, it would be important to include a 353 
sample with different CYP1A2 genotypes but with homogeneous habitual caffeine intake. 354 
 355 
Another important methodological aspect of the included studies is their sample size. Studies 356 
that found significant genotype differences included sample sizes ranging from 30 to 101 357 
participants. In contrast, most studies that did not find significant genotype differences 358 
involved smaller sample sizes, with one study conducted among a cohort of 11 participants 359 
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[20]. Because of the small sample size, some of the included studies might have been 360 
statistically underpowered to detect significant differences. While this might be the case, it 361 
should also be considered that the study by Spineli et al. [29] included 100 participants and 362 
did not find significant genotype differences, suggesting that the differences in sample sizes 363 
alone cannot be the explanation for the divergent findings. 364 
 365 
Methodological quality of the included studies 366 
We included studies published in peer-reviewed journals as well as theses and dissertations in 367 
this systematic review. This may be considered as a limitation given that studies published in 368 
journals might be of higher methodological quality, as the peer-review process is considered 369 
to present a form of quality control. Based on the PEDro checklist, however, all included 370 
studies were of good or excellent methodological quality, regardless of their publication 371 
status. Therefore, we believe that the inclusion of unpublished documents could be considered 372 
as a strength of the review due to “publication bias,” which dictates that studies reporting 373 
larger and statistically significant effect sizes tend to be more often published than studies 374 
reporting non-statistically significant data [52]. Therefore, basing the conclusions of a review 375 
only on the published literature may introduce a source of bias. Indeed, of the three 376 
unpublished documents included in the review, two did not report significant caffeine × 377 
genotype interaction, while one study was limited by the inclusion of only AC genotype in the 378 
review (i.e., no between-genotype comparison could be performed) [20, 21, 25].  379 
 380 
Practical application 381 
Based on the current body of research, it is questionable if the knowledge of the CYP1A2 382 
genotype represents a worthwhile means of informing caffeine-use strategies in sport. An 383 
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individual’s response to caffeine, and optimal caffeine-use strategy to increase performance, 384 
is likely complex, with aspects such as habitual caffeine use, method of caffeine intake, and 385 
situational feelings of stress and anxiety potentially influencing the response to a given dose 386 
of caffeine [7]. While there might be a genetic influence on the performance response to 387 
caffeine in sport, CYP1A2 represents only one such gene that has been demonstrated to 388 
potentially play a role, with others, such as ADORA2A tentatively identified [27, 28, 53, 54]. 389 
Future research, on a wider panel of genetic variants, should help to provide greater clarity 390 
here. For now, we suggest that athletes, coaches and support staff should take an evidence-391 
guided, experiential approach to caffeine, using current research-based guidelines as a starting 392 
point, and then utilizing self-experimentation to settle on a caffeine dose optimized for their 393 
unique make-up and circumstances. Finally, while the popularity of genetic testing in sport 394 
has increased in recent years [14], for those interested in caffeine supplementation, it currently 395 
seems that individual CYP1A2 genotype identification might not provide a definitive answer 396 
to the individual response to acute caffeine intake. 397 
 398 
Conclusion 399 
Based on the results of the studies included in the review, it seems that individuals with the 400 
CYP1A2 AA or AC/CC genotype may experience an increase in performance following 401 
caffeine ingestion. Even though significant differences between genotypes were found only in 402 
four studies, all four reported a more favorable response in the AA genotype. These results 403 
suggest that if there is an actual genotype-related effect of acute caffeine supplementation in 404 
the population, it is likely in that direction. In the studies that reported such data for aerobic 405 
endurance, the findings are specific to male participants performing cycling time trials 406 
(distances of ≥10 km) and ingesting caffeine 60 minutes before exercise. For high-intensity 407 
exercise, two studies reported that genotype variations determined the response to caffeine 408 
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ingestion, even though the differences were either small (~1 additional repetition in high-load 409 
resistance exercise set performed to failure) or inconsistent (i.e., observed only in one out of 410 
eight performance tests). In summary, CYP1A2 genotype variations may modulate caffeine's 411 
ergogenic effects, but the differences between genotypes were small, inconsistent, or limited 412 
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Table 1. Characteristics of the participants included in the studies 578 
Study Study sample  Habitual caffeine 
intake 
Genotype distribution 
Algrain et al. 
(2015)  
Recreationally active 
men and women (n = 
20) 
<300mg/day AA genotype, n = 11 (age: 24 ± 
2 years; mass: 76 ± 5 kg) 
AC/CC genotype, n = 9 (age: 26 
± 1 years; mass: 77 ± 6 kg) 
Carswell et 
al. (2020) 
Healthy active men 
and women (n = 18) 
13 participants were 
“low” users (0–150 
mg/day), 2 participants 
were “moderate” users 
(151–300 mg/day), and 
3 participants were 
“high” users (>300 
mg/day) 
AA genotype, n = 10 (age: 23 ± 
3 years; mass: 68 ± 11 kg) 
AC/CC genotype, n = 8 (age: 25 
± 5 years; mass: 74 ± 8 kg) 
Davenport et 
al. (2020)  
Well-trained male and 
female cyclists (n = 
13) 
≥50 mg/day AA genotype, n = 7 (age: 28 ± 2 
years; mass: 71 ± 2 kg) 
AC genotype, n = 6 (age: 28 ± 2 
years; mass: 71 ± 2 kg) 
Giersch et al. 
(2018) 
Recreationally-trained 
male cyclists (n = 20) 
93 ± 111 mg/day (AA 
genotype); 92 ± 137 
mg/day (AC/CC 
genotype)  
AA genotype, n = 8 (age: 24 ± 8 
years; mass: 72 ± 9 kg) 
AC/CC genotype, n = 12 (age: 
25 ± 7 years; mass: 75 ± 12 kg) 
Grgic et al. 
(2020) 
Resistance-trained 
men (n = 22)  
133 ± 123 mg/day (AA 
genotype), 117 ± 68 
mg/day (AC/CC 
genotype)  
AA genotype, n = 13 (age: 27 ± 
6 years; mass: 78 ± 7 kg) 
AC/CC genotype, n = 9 (age: 30 
± 4 years; mass: 81 ± 15 kg) 




Male athletes from 
endurance, power, or 
mixed-sports (n = 
101) 
For sport 
61 ± 13 mg/day (AA 
genotype), 89 ± 17 
mg/day (AC genotype), 
80 ± 74 mg/day (CC 
genotype) 
Dietary  
87 ± 18 mg/day (AA 
genotype), 80 ± 20 
mg/day (AC genotype), 
38 ± 24 mg/day (CC 
genotype) 
AA genotype, n = 49 (age: 24 ± 
4 years; mass: 80 ± 12 kg) 
AC genotype, n = 44 (age: 25 ± 
5 years; mass: 80 ± 10 kg) 
CC genotype, n = 8 (age: 25 ± 5 
years; mass: 93 ± 25 kg) 
Klein et al. 
(2012)  
Collegiate male and 
female tennis players 
(n = 16) 
104 ± 34 mg/day (AA 
genotype), 92 ± 64 
mg/day (AC/CC 
genotype) 
AA genotype, n = 7 (age: 21 ± 2 
years; mass: 71 ± 13 kg) 
AC/CC genotype, n = 9 (age: 21 
± 2 years; mass: 71 ± 13 kg) 
McGrath 
(2015)  
Well trained male 




27% “low” users, 45% 
“moderate” users, and 
27% “high” habitual 
caffeine users 
AA genotype, n = 6 (age: 31 ± 3 
years; mass: 77 ± 4 kg) 
AC/CC genotype, n = 5 (age: 31 
± 3 years; mass: 77 ± 4 kg) 
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Muñoz et al. 
(2020) 
Professional male and 
female handball 
players (n = 31) 
60 ± 25 mg/day AA genotype, n = 14 (age: 24 ± 
3 years; mass: 79 ± 16 kg) 
AC/CC genotype, n = 17 (age: 
24 ± 3 years; mass: 79 ± 16 kg) 
Pataky et al. 
(2016) 
Recreationally-trained 
male and female 
cyclists (n = 38) 
Average of 70 mg/day AA genotype, n = 21 (age: 20 ± 
1 years; mass: 68 ± 13 kg) 
AC genotype, n = 17 (age: 21 ± 
1 years; mass: 74 ± 8 kg) 
Potgieter 
(2013)  
Male and female 
triathletes (n = 26)  
413 ± 505 mg/day AA genotype, n = 16 (age: 38 ± 
11 years; mass: 69 ± 11 kg) 
AC/CC genotype, n = 10 (age: 
38 ± 11 years; mass: 69 ± 11 kg) 
Puente et al. 
(2018)  
Male and female elite 
basketball players (n = 
19) 
<100 mg per day AA genotype, n = 10 (age: 27 ± 
4 years; mass: 84 ± 19 kg) 
AC/CC genotype, n = 9 (age: 29 








AA genotype, n = 14 (age: 21 ± 
2 years; mass: 79 ± 19 kg) 
AC/CC genotype, n = 16 (age: 
22 ± 5 years; mass: 77 ± 11 kg) 
Salinero et al. 
(2017)  
Recreationally active 
men and women (n = 
21) 
<60 mg per day AA genotype, n = 5 (age: 29 ± 7 
years; mass: 69 ± 10 kg) 
AC/CC genotype, n = 16 (age: 




male athletes (n = 14) 
“All participants were 
regular users of 
caffeine” 
AC genotype, n = 14 (age: 27 ± 
8 years; mass: 77 ± 9 kg) 




competitive sports (n 
= 100) 
42 ± 39 mg/day (AA 
genotype), 59 ± 45 
mg/day (AC genotype), 
33 mg/day (CC 
genotype) 
AA genotype, n = 49 (age: 15 ± 
2 years; mass: 58 ± 10 kg) 
AC genotype, n = 42 (age: 16 ± 
2 years; mass: 58 ± 13 kg) 
CC genotype, n = 9 (age: 16 




cyclists (n = 35) 
86 ± 107 mg/day (AA 
genotype), 87 ± 145 
mg/day (AC/CC 
genotype)  
AA genotype, n = 16 (age: 24 ± 
7 years; mass: 74 ± 13 kg) 
AC/CC genotype, n = 19 (age: 
26 ± 8 years; mass: 74 ± 12 kg) 










Table 2. Summary of the caffeine intake protocols, exercise task(s), and main findings from 586 




Exercise task(s) Main findings Effect sizes 
Algrain et 
al. (2015)  
255 mg of caffeine 
consumed in a 
chewing gum 15-
minutes before 
starting the exercise 
session 
15-min of cycling 
at 75% VO2max, 10 
min of rest, and 15-
min cycling time 
trial 
No main effect of 
caffeine, and no 
caffeine × genotype 
interaction  
AA genotype: 0.16 




3 mg/kg of caffeine 
consumed in 
capsules 70-minutes 




A main effect of 
caffeine, but no 
caffeine × genotype 
interaction 




200 mg of caffeine 
consumed in a drink 
either 35-minutes 
before exercise, 
before 30-minutes of 
steady-state cycling, 
or immediately 
before a 15-minute 
cycling time trial a 
30 min of steady-
state cycling 
followed by and a 
15-minute cycling 
time trial  




minutes before the 
start of the exercise 
session, but no 




Whole sample: 0.35 
Before 30-minutes of 
steady-state cycling  
Whole sample: 0.17 
Before a 15-minute 
cycling time trial 
Whole sample: 0.06 
Giersch et 
al. (2018) 
6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session 
3-km cycling time 
trial 
A main effect of 
caffeine, but no 
caffeine × genotype 
interaction 
AA genotype: 0.37 
AC/CC genotype: 0.25 
Grgic et 
al. (2020) 
3 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session 
Movement velocity 
and power in the 
bench press with 
different loads, one 
set of bench press 





A main effect of 
caffeine in all 
exercise tests, but 
no caffeine × 
genotype 
interaction 
Movement velocity and 
power in the bench press 
AA genotype: 0.14–0.69 
AC/CC genotype: 0.23–
0.85 
Muscle endurance and 
velocity 




AA genotype: 0.19 
AC/CC genotype: 0.15 
Power output in the 
Wingate 













starting the exercise 
session 
10-km cycling time 
trial 
A main effect of 
caffeine and 








ingestion (both 2 
and 4 mg/kg), those 
with the AC 
genotype did not 
improve 
performance with 
any of the caffeine 
doses, and 
performance of 
those with the CC 
genotype was 
worse with the 
ingestion of 4 
kg/mg but not 2 
mg/kg of caffeine 
2 mg/kg 
AA genotype: 0.33 
AC genotype: 0.07 
CC genotype: (data not 
presented) 
4 mg/kg 
AA genotype: 0.49 
AC genotype: 0.20 
CC genotype: –1.35 
Klein et al. 
(2012)  
6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 






by a tennis skill test 
A main effect of 
caffeine, but no 
caffeine × genotype 
interaction 
AA genotype: 0.48 
AC/CC genotype: 0.62 
McGrath 
(2015)  
5 mg/kg of caffeine 
consumed in 
capsules 60-minutes 




followed by a 30-
minute time trial 
A main effect of 
caffeine, but no 
caffeine × genotype 
interaction 
Whole sample: 0.59 
Muñoz et 
al. (2020) 
3 mg/kg of caffeine 
consumed in 
capsules 60-minutes 







ball throw from 7-
m, ball throw from 
7-m with a 
goalkeeper, ball 
throw from 9-m, 
and ball throw 
from 9-m with a 
goalkeeper 
 
A main effect of 
caffeine for CMJ 
height, time in the 
sprint velocity test, 
and ball throw 
velocity from 9-m, 
but no caffeine × 
genotype 
interaction. No 
main effect of 






AA genotype: 0.28 
AC/CC genotype: 0.15 
Sprint velocity test 
AA genotype: 0.84 
AC/CC genotype: 0.15 
Modified agility t-test 
AA genotype: 0.03 
AC/CC genotype: –0.05 
Isometric handgrip 
strength  
AA genotype: 0.00 
AC/CC genotype: 0.23 
Ball throw from 7-m 
AA genotype: 0.34 
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ball throw velocity 
from 7-m with a 
goalkeeper, ball 
throw velocity 
from 9-m with a 
goalkeeper, and no 
caffeine × genotype 
interaction. No 
main effect of 
caffeine for ball 
throw velocity 
from 7-m, but a 
caffeine × genotype 
interaction whereby 
participants with 





those with the 
AC/CC genotype 
did not 
AC/CC genotype: –0.02 
Ball throw from 7-m with 
a goalkeeper 
AA genotype: 0.39 
AC/CC genotype: –0.23 
Ball throw from 9-m 
AA genotype: 0.40 
AC/CC genotype: 0.22 
Ball throw from 9-m with 
a goalkeeper 
AA genotype: 0.47 
AC/CC genotype: 0.05 
Pataky et 
al. (2016)  
6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session, 
with or without 
additional caffeine 
mouth rinsing  
3-km cycling time 
trial 
A main effect of 
caffeine when 
caffeine ingestion 
was combined with 
mouth rinsing; 
using MBI, the 
effects favored the 
AC genotype, but 
the effect was not 
statistically 
significant (p = 
0.12) 
Data not presented 
Potgieter 
(2013)  
6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 




A main effect of 
caffeine, but no 
caffeine × genotype 
interaction 
Whole sample: 0.10 
Puente et 
al. (2018)  
3 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session 
Abalakov jump 




with and without 
the ball 
A main effect of 
caffeine for 
Abalakov jump 
height, but no 
caffeine × genotype 
interaction; no 
main effect of 
caffeine for sprint 
time in the 
“Change-of-
Abalakov jump 
AA genotype: 0.15 
AC/CC genotype: 0.14 
“Change-of-Direction 
and Acceleration Test” 
without the ball  
AA genotype: 0.12 





with or without the 




and Acceleration Test” 
with the ball  
AA genotype: 0.44 
AC/CC genotype: 0.0 
Rahimi 
(2018)  
6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session 
3 sets performed to 
muscle failure with 
85% 1RM in the 
bench press, leg 
press, seated row, 
and shoulder press 
A main effect of 
caffeine and 
caffeine × genotype 
interaction in all 
exercises, whereby 
participants with 









AA genotype: 0.88–1.87 
AC/CC genotype: –0.05 
to 0.09 
Leg press 
AA genotype: 0.48–1.22 
AC/CC genotype: –0.12 
to 0.44 
Seated row 









3 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session 
30-second Wingate A main effect of 
caffeine for peak 
and mean power, 




AA genotype: 0.04 
AC/CC genotype: 0.15 
Mean power 
AA genotype: 0.07 
AC/CC genotype: 0.10 
Southward 
(2016) 
6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 





extension, SJ and 
CMJ 
A main effect of 
caffeine for 
eccentric knee 
extensor torque and 
SJ height; no 
significant 
difference for the 
10-km time trial, 
concentric knee 
extensor torque and 
CMJ height 
10-km running time trial 
AC genotype: 0.34 
Concentric knee extensor 
torque 
AC genotype: 0.25 
Eccentric knee extensor 
torque 
AC genotype: 0.44 
SJ height 
AC genotype: 0.33 
CMJ height 
AC genotype: 0.17 
Spineli et 
al. (2020) 
6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session 




sit-up, and Yo-Yo 
IR1 
A main effect of 
caffeine for push-
up and sit-up 
repetitions and 
distance covered in 
the Yo-Yo IR1, but 
no caffeine × 
genotype 
interaction. No 
main effect and no 
CMJ 
AA genotype: 0.11 
AC genotype: 0.13 
CC genotype: 0.04 
Spike jump 
AA genotype: 0.14 
AC genotype: 0.05 
CC genotype: 0.01 
Agility test 
AA genotype: 0.10 
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caffeine × genotype 
interaction for CMJ 
height, spike jump 
height, and time in 
the agility test 
AC genotype: 0.07 
CC genotype: –0.37 
Isometric handgrip 
strength  
AA genotype: 0.17 
AC genotype: 0.07 
CC genotype: 0.06 
Push-up 
AA genotype: 0.09 
AC genotype: 0.24 
CC genotype: 0.36 
Sit-up 
AA genotype: 0.24 
AC genotype: 0.32 
CC genotype: 0.28 
Yo-Yo IR1 
AA genotype: 0.31 
AC genotype: 0.36 




6 mg/kg of caffeine 
consumed in 
capsules 60-minutes 
before starting the 
exercise session 
40-km cycling time 
trial 
A main effect of 
caffeine and 




performance by a 
greater magnitude 
in the AA genotype 
in comparison with 
the AC/CC 
genotype  
AA genotype: 0.67 
AC/CC genotype: 0.34 
SJ: squat jump; CMJ: countermovement jump; 1RM: one-repetition maximum; MBI: magnitude-based 
inferences; IR1: intermittent recovery test level 1; VO2max: maximum rate of oxygen consumption; a the 
drink contained other substances such as beta-alanine and quercetin, which are not considered ergogenic 












Table 3. Results of the methodological quality assessment using the Physiotherapy Evidence-597 
Based Database (PEDro) scale.  598 
Reference Item 
1 


















al. (2015)  








Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Giersch et 
al. (2018) 
No Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Grgic et 
al. (2020a) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Guest et 
al. (2018) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Klein et 
al. (2012) 
Yes Unclear Unclear Yes Yes Yes Yes No Yes Yes Yes 7 
McGrath 
(2015) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes No 8 
Muñoz et 
al. (2020) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Pataky et 
al. (2016) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Potgieter 
(2013) 
Yes Yes Unclear Yes Yes Yes Yes No Yes Yes No 7 
Puente et 
al. (2018) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Rahimi 
(2018) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Salinero et 
al. (2017) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Southward 
(2016) 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 
Spineli et 
al. (2020) 




Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes Yes 9 















































Studies included in the review 
from the primary search 
(n = 14) 
Studies included in the 
review  








Full-text articles assessed 
for eligibility (n = 28)  
 
 
Full-text articles excluded (n = 
14), with the following reasons: 
• Conference abstract (n = 6) 
• Duplicate data (n = 3) 
• No exercise tasks (n = 3) 
• Unsuitable outcome (n = 2) 
 
Secondary searches 
(n = 1684) 
Records screened  
(n = 1621) 
 
 
Records identified through 
database searching  
(n = 1621) 
 
 
Excluded based on title or abstract 
(n = 1593) 
 
Studies additionally included from 
the secondary searches 
(n = 3) 
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